Akebia Therapeutics Inc. AKBA

NAS: AKBA | ISIN: US00972D1054 11/07/2025

3,930 USD (-1,26%)

(-1,26%) 11/07/2025

Grafiek Akebia Therapeutics Inc.

Grafiek Akebia Therapeutics Inc.

1 dag1d -1,26%
1 week1w 8,26%
1 maand1m 7,67%
3 maanden3m 114,75%
6 maanden6m 110,16%
1 jaar1j 211,90%
5 jaar5j -66,78%

Akebia Therapeutics Inc. in het nieuws

Toon enkel gratis nieuws

5 september 2024 · Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis · Persbericht

3 september 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

26 augustus 2024 · Akebia Therapeutics to Present at Upcoming Investor Conferences · Persbericht

8 augustus 2024 · Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights · Persbericht

2 augustus 2024 · Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights · Persbericht

1 augustus 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

29 juli 2024 · Akebia Therapeutics to Present at Upcoming Investor Conferences · Persbericht

11 juli 2024 · Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets · Persbericht

1 juli 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

27 juni 2024 · Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference · Persbericht

Profiel Akebia Therapeutics Inc.

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: akebia.com

Hoofdzetel: Cambridge, Massachusetts Verenigde Staten

CEO: John Butler

Werknemers: 353

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe